Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

UroGen Pharma (URGN) Enterprise Value (2016 - 2025)

Historic Enterprise Value for UroGen Pharma (URGN) over the last 10 years, with Q3 2025 value amounting to -$127.0 million.

  • UroGen Pharma's Enterprise Value rose 4910.03% to -$127.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$127.0 million, marking a year-over-year increase of 4910.03%. This contributed to the annual value of -$236.7 million for FY2024, which is 7280.31% down from last year.
  • Latest data reveals that UroGen Pharma reported Enterprise Value of -$127.0 million as of Q3 2025, which was up 4910.03% from -$157.0 million recorded in Q2 2025.
  • Over the past 5 years, UroGen Pharma's Enterprise Value peaked at -$47.3 million during Q2 2023, and registered a low of -$249.6 million during Q3 2024.
  • Over the past 5 years, UroGen Pharma's median Enterprise Value value was -$127.0 million (recorded in 2025), while the average stood at -$135.3 million.
  • Its Enterprise Value has fluctuated over the past 5 years, first skyrocketed by 5232.18% in 2023, then tumbled by 40966.79% in 2024.
  • UroGen Pharma's Enterprise Value (Quarter) stood at -$89.1 million in 2021, then fell by 12.14% to -$100.0 million in 2022, then plummeted by 37.02% to -$137.0 million in 2023, then tumbled by 72.8% to -$236.7 million in 2024, then skyrocketed by 46.33% to -$127.0 million in 2025.
  • Its last three reported values are -$127.0 million in Q3 2025, -$157.0 million for Q2 2025, and -$195.9 million during Q1 2025.